Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Volunteer first responders for out-of-hospital cardiac arrest at home: the missing link for improved survival?

    Research output: Contribution to journalEditorialResearchpeer-review

  3. Risk of sports-related sudden cardiac death in women

    Research output: Contribution to journalReviewResearchpeer-review

  1. Three decades of heart transplantation: experience and long-term outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Real-world data on melanoma brain metastases and survival outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care

    Research output: Contribution to journalReviewResearchpeer-review

  4. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: The study aimed to estimate the risk of cardiac events in immune checkpoint inhibitor (ICI)-treated patients with lung cancer or malignant melanoma.

METHODS AND RESULTS: The study included consecutive patients with lung cancer or malignant melanoma in 2011-17 nationwide in Denmark. The main composite outcome was cardiac events (arrhythmia, peri- or myocarditis, heart failure) or cardiovascular death. Absolute risks were estimated and the association of ICI and cardiac events was analysed in multivariable Cox models. We included 25 573 patients with lung cancer. Of these, 743 were treated with programmed cell death-1 inhibitor (PD1i) and their 1-year absolute risk of cardiac events was 9.7% [95% confidence interval (CI) 6.8-12.5]. Of the 13 568 patients with malignant melanoma, 145 had PD1i and 212 had cytotoxic T-lymphocyte-associated protein-4 inhibitor (CTLA-4i) treatment. Their 1-year risks were 6.6% (1.8-11.3) and 7.5% (3.7-11.3). The hazard rates of cardiac events were higher in patients with vs. without ICI treatment. Within 6 months from 1st ICI administration, the hazard ratios were 2.14 (95% CI 1.50-3.05) in patients with lung cancer and 4.30 (1.38-13.42) and 4.93 (2.45-9.94) in patients with malignant melanoma with PD1i and CTLA-4i, respectively. After 6 months, HRs were 2.26 (1.27-4.02) for patients with lung cancer and 3.48 (1.91-6.35) for patients with malignant melanoma and CTLA-4i.

CONCLUSIONS: Among patients with lung cancer and malignant melanoma, ICI treated had increased rates of cardiac events. The absolute risks were higher in these data compared with previous pharmacovigilance studies (e.g. 1.8% peri-/myocarditis 1-year risk).

Original languageEnglish
JournalEuropean Heart Journal
Volume42
Issue number16
Pages (from-to)1621-1631
Number of pages11
ISSN0195-668X
DOIs
Publication statusPublished - 21 Apr 2021

    Research areas

  • Arrhythmia, Cardio-oncology, Cardiovascular death, Heart failure, Immune checkpoint inhibitors, Myocarditis

ID: 61434338